glp-1 reimbursement news The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs GLP-1 use rises

Zepbound and Wegovy are FDA-approved for weight loss, Ozempic is approved for type 2 diabetes, has been used off-label for weight loss, if appropriate

GLP-1 receptor agonists, originally developed for diabetes and weight management, are emerging as promising non-hormonal options to reduce cardiovascular risk in estrogen-deficient women

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, DAlessio DA, Haupt A

The theoretical benefits of low-dose GLP-1 therapy for inflammation include the potential for anti-inflammatory effects with a reduced side effect burden compared to standard doses

The glucagon-like peptide-1 receptoror not